Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, and Crown CRO, a contract research organization based in Finland, today announced Crown’s engagement to manage Adial’s Phase 3 clinical trial for AD04 for the treatment of alcohol use disorder (AUD). The FDA approved protocol for this Phase 3 clinical trial is a 24-week trial with 290 patients in 30 clinical sites in 5 European countries.
Study nurse training – introducing a nationwide, fully web-based program (Crown CRO is proud to participate)
The first nationwide study nurse training program (worth four academic […]
Crown CRO is proud to recognize World Cancer Day – a day of unification to combat cancer across the globe
Today, on the 4th of February is World Cancer Day. […]
Article in Finnish: https://yle.fi/uutiset/3-11696658
Drug development never stops; new molecules are clinically tested and […]
The development of new drugs and treatments is a long […]